FEATURED CONTENT

Accelerate test internalization with PGDx elio™ plasma focus Dx, an FDA-authorized liquid biopsy-based genomic profiling solution

Liquid biopsy next-generation sequencing (NGS) assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable or during disease progression. Extensive analytical validation of the targeted 33-gene assay, PGDx elio plasma focus Dx, has shown that detection of cancer-associated variants in circulating tumor DNA (ctDNA) is highly specific, sensitive, reproducible and accurate. Distribution of this kitted assay, including automated machine-learning software to generate reports, can inform precision oncology decision-making.

Learning Objectives

  • Use of comprehensive genomic profiling (CGP) and liquid biopsies in clinical workflows for cancer patients
  • Specifications and workflow of the PGDx elio plasma focus Dx assay
  • Validation efforts for FDA authorization of PGDx elio plasma focus Dx

Watch Webinar

Watch our webinar to learn how Labcorp’s PGDx elio™ plasma focus Dx can accelerate test internalization

Watch Webinar
Sign up to view resources
By submitting this form, you affirm that you have read and understand the Privacy Policy and Terms of Use.
RESOURCES

Educational tools to facilitate local comprehensive genomic profiling implementation

FDA-authorized tissue and liquid biopsy kitted assays from Labcorp
PGDx elio™ plasma focus Dx: The first FDA-authorized pan solid tumor liquid biopsy kitted solution
Research highlights from AMP 2024